
Recent years have seen calls for genetic testing for all patients with breast cancer. A session at the 2020 San Antonio Breast Cancer Symposium reviewed the evidence for, and against, such testing.

Recent years have seen calls for genetic testing for all patients with breast cancer. A session at the 2020 San Antonio Breast Cancer Symposium reviewed the evidence for, and against, such testing.

Due to a lack of comprehensive data on health literacy among these patients, a team of investigators looked at its connection with their quality of life (QOL).

A funding dispute over how to account for a Veterans Affairs (VA) health care program is stalling deal to fund the government for another year; the Supreme Court rules in a case involving states and pharmacy benefit managers (PBMs); the antiepileptic drug ezogabine lowered the pathologic excitability of cortical and spinal motor neuron cells, which have a role in amyotrophic lateral sclerosis (ALS).

Hope Rugo, MD, director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the benefits of oral paclitaxel in metastatic breast cancer.

Researchers identified new genetic associations that can predict individuals’ susceptibility to Takayasu arteritis, a rare type of vasculitis.

Gregory Vidal, MD, PhD, West Cancer Center and Research Institute, discusses the methodology of the Neat-HER study on neratinib in the extended adjuvant setting in HER2-positive breast cancer.

A spotlight poster discussion at SABCS highlighted topics in genomic testing, potentially game-changing therapies, and predictive biomarkers in HR-positive breast cancer.

The panel was charged with deciding if the benefits of the vaccine outweighs the risks, paving the way for the possibility that immunizations could begin within days.

Childhood abuse, household dysfunction, and neglect were linked in a recent study to an increased risk of developing cardiovascular disease in adulthood.

Results from a 5-year study show significantly higher rates of several gastrointestinal (GI) disorders, as well as hospital-related costs, among patients living with HIV compared with controls.

Investigators concluded that use of a new registry could aid in the recruitment of pediatric subjects with severe asthma and the design of future clinical trials for emerging biologics.

What people believe about health and public health, although challenged before the coronavirus disease 2019 (COVID-19) pandemic, is even more crucial now as vaccine distribution efforts could soon begin.

During the enactment period of recent Michigan opioid laws, a reduction in opioid prescriptions for oculoplastic and orbital procedures was observed and appeared to be sustained, according to research published in JAMA Ophthalmology.

The United States reports a record 3000 daily coronavirus disease 2019 (COVID-19) deaths; the House of Representatives passes bill in support of marijuana research; data show rises in prescription drug list prices.

Poster presentations at the San Antonio Breast Cancer Symposium demonstrated the clinical relevance and efficacy of oral paclitaxel plus encequidar in the treatment of metastatic breast cancer.

Researchers review the association between Parkinson disease and dermatologic disorders, as well as implications that this link may have on the pathophysiological mechanisms underlying Parkinson disease.

Kazia Therapeutics will report the full results at a future scientific meeting.

A new study helps explain immunological factors that appear to have an impact on the success rate of mogamulizumab in patients with adult T-cell leukemia-lymphoma (ATL).

During the San Antonio Breast Cancer Symposium 2020, Lajos Pusztai, MD, DPhil, of Yale Cancer Center, reviewed recently established and emerging biomarkers in both the neoadjuvant and metastatic breast cancer settings.

The science around risk stratification in patients with smoldering multiple myeloma (SMM) has been evolving over the past 2 decades. A new study validates some, though not all, of the proposed biomarkers.

Yuan Yuan, MD, PhD, medical oncologist at City of Hope, discusses an ongoing study on ipatasertib with chemotherapy and atezolizumab presented at the San Antonio Breast Cancer Symposium 2020.

Researchers found the application of FOLFOXai, an artificial intelligence (AI)–based predictor of response to FOLFOX chemotherapy in metastatic colorectal cancer (mCRC), may lead to improved treatment outcomes for some patients with mCRC and other cancers.

Pfizer CEO shares his expectations for its coronavirus disease 2019 (COVID-19) vaccine approval; peer review results are in for AstraZeneca and Oxford University’s COVID-19 vaccine candidate; there are now competing legislative proposals on surprise medical billing protection.

New devices can help to manage sleep apneas, but underlying conditions must be treated, too, noted Krishna M. Sundar, MD, clinical professor, Pulmonary Division, Department of Medicine, medical director, Sleep-Wake Center, University of Utah.

The pandemic's effects on migraine need to be evaluated for the whole of 2020 and data from one specific time are not enough, said Faraidoon Haghdoost, MD, a general practitioner and PhD student at The George Institute for Global Health in Sydney, Australia.

A panel at the 2020 San Antonio Breast Cancer Symposium discussed 3 new drug approvals from the past year, highlighting changes in the treatment landscape across multiple breast cancer types.

Top reasons why patients with heart failure face a higher risk of hospitalization during times when fracking occurs include an increase in air pollution and stress pathways.

Rachel Jimenez, MD, radiation oncologist at Massachusetts General Hospital, outlines the prevalence of cardiac toxicity, as well as the short-term and long-term impacts.

Among women hospitalized with coronavirus disease 2019 (COVID-19), use of metformin—a type 2 diabetes (T2D) drug used to manage blood sugar levels—was associated with a 21.5% lower risk of death.

Inqovi is an orally administered, fixed-dose combination of the DNA hypomethylating agent, decitabine, and cedazuridine, an inhibitor of cytidine deaminase.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
